secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001193805-23-001112
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcturus Q2 net loss widens to $52.6M; ARCT-154 NDA submitted in Japan
----------------------------------------------------------------------

- Q2 2023 revenue $10.5M vs $27.1M in Q2 2022; net loss $52.6M ($1.98 EPS) vs $21.6M loss ($0.82 EPS).
- Cash, equivalents and restricted cash $380.6M at June 30; cash runway extended through early 2026.
- ARCT-154 Phase 3 booster met primary endpoint; Meiji Seika Pharma submitted NDA in Japan.
- FDA granted Fast Track and Rare Pediatric Disease Designations for ARCT-810 (OTC deficiency).
- Regulatory approval received to start ARCT-032 Phase 1b study in cystic fibrosis patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380523001112/0001193805-23-001112-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380523001112/e618839_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-23-001112

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer